Transthyretin Amyloid Cardiomyopathy

• FDA approval · 2021-06-01
  FDA Approved: VYNDAMAX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

  FDA approved a supplemental application for VYNDAMAX (tafamidis) submitted by Pfizer Laboratories Div Pfizer Inc.

• CLINICAL_TRIALS trial_result · 2021-01-05
  Clinical Trial Update: Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy [Phase 3]

  Phase 3 trial update evaluating Fx-1006a in patients with ATTR-CM (TTR-CM) has completed, with results posted in 2021.

• CLINICAL_TRIALS trial_result · 2020-12-04
  Clinical Trial Update: Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy [Phase 1, Phase 2]

  Phase 1/2 trial investigating doxycycline and TUDCA in transthyretin amyloid cardiomyopathy has completed with results posted.

• CLINICAL_TRIALS trial_result · 2019-04-03
  Clinical Trial Update: Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy [Phase 3]

  Phase 3 clinical trial assessing safety and efficacy of tafamidis in transthyretin cardiomyopathy has completed with results posted.

• CLINICAL_TRIALS trial_result · 2013-05-21
  Clinical Trial Update: A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc) [Phase 1]

  Phase 1 trial evaluating whether tafamidis affects QTc intervals in transthyretin amyloid cardiomyopathy. The study has completed.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2012-12-18
  Clinical Trial Update: The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy [Phase 2]

  Pfizer completed a Phase 2 trial evaluating Fx-1006A for stabilizing transthyretin and improving clinical outcomes in patients with transthy…